ISHLT Consensus Statement on Strategies to Prevent and Manage Hemocompatibility Related Adverse Events in VAD Patients [1]
This consensus statement disseminated by the International Society for Heart and Lung Transplantation (ISHLT) focuses on the prevention and management of hemocompatability-related adverse events (HRAEs) in patients with durable, continuous-flow left ventricular assist devices (CF-LVAD). As survival in this group of patients continues to improve with advances in technology, HRAEs remain a concern. The ISHLT summarizes the literature in this field and shares several recommendations including management of antiplatelet agents, oral anticoagulation, management of high-risk patients, and management of bleeding or clotting events based on different existing devices.